Ru Back Packer

Quotes delayed 20 minutes



If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Free Preferred Stock Newsletter
Gain access to weekly reports with featured preferred stock screens, new preferred stock offerings, and more.

Slideshow Preferred Stock Offerings

By Ru Back Packer Staff, updated Sunday, January 28, 9:08 AM

Slide #275. Dynavax Technologies Corporation Preferred Stock Offering

Company: Dynavax Technologies Corporation (NASDAQ:DVAX)
Date announced: 10/24/2013
Shares Offered: 43,430
Date of Pricing: 10/25/2013
Price Per Share: $1,075.00
Preferred Stock Offering Details: Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to concurrently offer to sell, subject to market and other conditions: (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series B Convertible Preferred Stock ("Series B") in a separate underwritten public offering. The Series B is non-voting and convertible into shares of Dynavax common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.98% of the total number of shares of Dynavax common stock then outstanding. Dynavax anticipates using the net proceeds from the offerings primarily to fund development activities predominantly associated with conducting an additional Phase 3 study of HEPLISAV and seeking regulatory approval to commercialize the vaccine in the United States and Europe, and for other general corporate purposes, including working capital.

Dynavax Technologies is a clinical-stage immunotherapy company. Co.'s product candidates are being investigated for use in several cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Co.'s key cancer immunotherapy candidate is SD-101, a C Class CpG toll-like receptor 9 agonist that was selected for characteristics optimal for treatment of cancer, including high interferon induction In addition, Co.'s product candidate, HEPLISAV-B, is an investigational adult hepatitis B vaccine. Furthermore, AZD1419 is being developed for the treatment of asthma pursuant to a collaboration with AstraZeneca AB.
Open the DVAX Page at Ru Back Packer »

Name: Dynavax Technologies Corp
Website: dynavax.com
Sector: Biotechnology
Number of ETFs Holding DVAX: 20 (see which ones)
Total Market Value Held by ETFs: $103,987,137
Total Market Capitalization: $1,051,000,000
% of Market Cap. Held by ETFs: 9.89%

Open the DVAX Page at Ru Back Packer (in a new window) »

Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference

The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500

Preferred Stock Offerings - Slide 275 of 414 | rubackpacker.com | Copyright © 2011 - 2018, All Rights Reserved